Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ABL Mutation Register in Patients With ITK Relapsed or Refractory Chronic Myeloid Leukemia

NCT05080829 is registered in ClinicalTrials.gov with Grupo Cooperativo de Hemopatías Malignas as lead sponsor.

NCT NCT05080829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05080829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ABL Mutation Register in Patients With ITK Relapsed or Refractory Chronic Myeloid Leukemia
Lead sponsor
Grupo Cooperativo de Hemopatías Malignas
Phase
Not applicable
Overall status
Unknown status
Start date
March 1, 2021
Completion date
March 30, 2022
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukaemia recurrent, chronic myeloid leukemia, in relapse